title: Kava chalcone, flavokawain A, inhibits urothelial tumorigenesis in the UPII-SV40T transgenic mouse model.
abstract: Flavokawain A (FKA) is the predominant chalcone identified from the kava plant. We have previously shown that FKA preferentially inhibits the growth of p53 defective bladder cancer cell lines. Here, we examined whether FKA could inhibit bladder cancer development and progression in vivo in the UPII-SV40T transgenic model that resembles human urothelial cell carcinoma (UCC) with defects in the p53 and the retinoblastoma (Rb) protein pathways. Genotyped UPII-SV40T mice were fed orally with vehicle control (AIN-93M) or FKA (6 g/kg food; 0.6%) for 318 days starting at 28 days of age. More than 64% of the male mice fed with FKA-containing food survived beyond 318 days of age, whereas only about 38% of the male mice fed with vehicle control food survived to that age (P = 0.0383). The mean bladder weights of surviving male transgenic mice with the control diet versus the FKA diet were 234.6 ± 72.5 versus 96.1 ± 69.4 mg (P = 0.0002). FKA was excreted primarily through the urinary tract and concentrated in the urine up to 8.4 μmol/L, averaging about 38 times (males) and 15 times (females) more concentrated than in the plasma (P = 0.0001). FKA treatment inhibited the occurrence of high-grade papillary UCC, a precursor to invasive urothelial cancer, by 42.1%. A decreased expression of Ki67, survivin, and X-linked inhibitor of apoptotic proteins (XIAP) and increased expression of p27 and DR5, and the number of terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL)-positive apoptotic cells were observed in the urothelial tissue of FKA-fed mice. These results suggest a potential of FKA in preventing the recurrence and progression of non-muscle-invasive UCC.
authors.affiliation: Department of Urology, University of California, Irvine, 101 The City Drive South, Rt. 81 Bldg. 55 Rm. 302, Orange, CA 92868. xzi@uci.edu.
authors.forename: Zhongbo
authors.initials: Z
authors.lastname: Liu
authors.forename: Xia
authors.initials: X
authors.lastname: Xu
authors.forename: Xuesen
authors.initials: X
authors.lastname: Li
authors.forename: Shuman
authors.initials: S
authors.lastname: Liu
authors.forename: Anne R
authors.initials: AR
authors.lastname: Simoneau
authors.forename: Feng
authors.initials: F
authors.lastname: He
authors.forename: Xue-Ru
authors.initials: XR
authors.lastname: Wu
authors.forename: Xiaolin
authors.initials: X
authors.lastname: Zi
mesh_terms: D000818:Animals; D000952:Antigens, Polyomavirus Transforming / Q000378:metabolism*; D017209:Apoptosis; D015139:Blotting, Southern; D015153:Blotting, Western; D049109:Cell Proliferation; D002471:Cell Transformation, Neoplastic / Q000187:drug effects* / Q000235:genetics / Q000473:pathology; D002599:Chalcone / Q000031:analogs & derivatives* / Q000032:analysis / Q000494:pharmacology; D002853:Chromatography, Liquid; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D020901:Kava / Q000737:chemistry*; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D053719:Tandem Mass Spectrometry; D001749:Urinary Bladder Neoplasms / Q000235:genetics / Q000473:pathology / Q000517:prevention & control*; D060170:Uroplakin II / Q000235:genetics*
chemical_list: D000952:Antigens, Polyomavirus Transforming; D060170:Uroplakin II; C500809:flavokawain A; D002599:Chalcone